Graph AI, a California-based AI company specializing in drug safety and pharmacovigilance, has secured $3 million in seed funding, with Bessemer Venture Partners at the helm.

The startup intends to utilize the funds to enhance product development, grow its engineering team, and speed up the adoption of its automation platform by pharmaceutical companies worldwide.

Established in 2024 by Raghav Parvataraju, Vijay Ponukumati, Mohan Konyala, and Ashutosh Bordekar, Graph AI seeks to innovate the methods by which pharmaceutical companies identify and document adverse drug events, a field that relies significantly on manual, labor-intensive methods. The founders formerly occupied positions at LTI Mindtree, Infosys, ServiceNow, Google, and Cisco.

The company's primary platform, Graph Safety, employs context-aware AI to automate functions like case processing, signal detection, and regulatory reporting, while ensuring human oversight is maintained for essential monitoring tasks.

Also Read: WAVES Summit 2025: Paving Way for Tech Pluralism

Pharmacovigilance, required by authorities worldwide, necessitates that pharmaceutical companies consistently track and report possible side effects from clinical trials during post-marketing usage.

Typically, the task is contracted to major service companies that depend on groups of pharmacology graduates to analyze unstructured data like medical records, call logs, and legal documents. Graph AI claims its technology can accelerate this process by up to 90 percent and enhance efficiency by 70 percent, minimizing compliance delays and operational expenses.

Also Read: Karnataka to Become Quantum Capital of Asia Soon

“Companies in the life sciences sector continue to face challenges with obsolete, disjointed systems that hinder timely decision-making,” the founders expressed in a unified statement. “We're creating an AI-driven safety platform that combines context, compliance, and intelligence to assist organizations in achieving safer results and enhanced regulatory assurance.”

Also Read: The Global Fintech Fest 2025: Enabling Finance for Better World

Nithin Kaimal, COO and partner at Bessemer’s India, stated that the company’s investment demonstrates belief in AI’s ability to transform delivery from labor arbitrage to intelligence arbitrage,” changing conventional service-intensive models into scalable, tech-driven systems.

Graph AI has launched its platform with corporate clients and is creating a pipeline that includes more than 7,000 marketed medications.